However, the results of a clinical trial of the MEK inhibitor selumetinib in KRAS-mutated advanced NSCLC patients were perplexing, as high TH17 levels at baseline and increased TH17 levels after treatment were associated with response and better PFS, respectively [168]. Here, KRAS is linked to non-small cell lung carcinoma.